Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells - PubMed (original) (raw)
Galina V Mikheeva, Victor Krasnykh, Candace J Coolidge, John T Lam, Parameshwar J Mahasreshti, Shannon D Barker, Michael Straughn, Mack N Barnes, Ronald D Alvarez, Akseli Hemminki, David T Curiel
Affiliations
- PMID: 11801569
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells
Anna Kanerva et al. Clin Cancer Res. 2002 Jan.
Abstract
Gene delivery efficiency in clinical cancer gene therapy trials with recombinant adenoviruses (Ads) based on serotype 5 (Ad5) has been limited partly because of variable expression of the primary Ad5 receptor, the coxsackie and adenovirus receptor (CAR), on human primary cancer cells. As a means of circumventing CAR deficiency, Ad vectors have been retargeted by creating chimeric fibers possessing knob domains of alternate Ad serotypes. In this study, we have constructed an Ad5-based vector, Ad5/3luc1, with a chimeric fiber protein featuring a knob domain derived from Ad3. This virus is retargeted to the Ad3 receptor and, therefore, has different tissue tropism. A novel knob binding assay was used to measure expression of CAR and the Ad3 receptor. Further, to evaluate the correlation of receptor expression and infectivity by Ad, a panel of ovarian cancer cell lines and purified primary cancer cells were infected with Ad5luc1 and Ad5/3luc1 at 50, 200, and 1000 viral particles/cell. Our results confirm that Ad5/3luc1 is retargeted to the Ad3 receptor. Furthermore, the Ad3 receptor is present at higher levels than CAR on ovarian adenocarcinoma cells. Also, the amount of binding to primary receptor appears to be the major factor determining the efficiency of transgene expression. The Ad5/3 chimera displays enhanced infectivity for ovarian cancer cell lines and purified primary tumor cells, which could translate into increased efficacy in clinical trials.
Similar articles
- A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.
Stoff-Khalili MA, Rivera AA, Glasgow JN, Le LP, Stoff A, Everts M, Tsuruta Y, Kawakami Y, Bauerschmitz GJ, Mathis JM, Pereboeva L, Seigal GP, Dall P, Curiel DT. Stoff-Khalili MA, et al. Gene Ther. 2005 Dec;12(23):1696-706. doi: 10.1038/sj.gt.3302588. Gene Ther. 2005. PMID: 16034451 - Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.
Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A. Kanerva A, et al. Mol Ther. 2002 Jun;5(6):695-704. doi: 10.1006/mthe.2002.0599. Mol Ther. 2002. PMID: 12027553 - Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity.
Krasnykh V, Dmitriev I, Navarro JG, Belousova N, Kashentseva E, Xiang J, Douglas JT, Curiel DT. Krasnykh V, et al. Cancer Res. 2000 Dec 15;60(24):6784-7. Cancer Res. 2000. PMID: 11156365 Review. - Cancer-targeting gene therapy using tropism-modified adenovirus.
Tanaka T, Kuroki M, Hamada H, Kato K, Kinugasa T, Shibaguchi H, Zhao J, Kuroki M. Tanaka T, et al. Anticancer Res. 2007 Nov-Dec;27(6A):3679-84. Anticancer Res. 2007. PMID: 17970028 Review.
Cited by
- Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.
Kudling TV, Clubb JHA, Pakola S, Quixabeira DCA, Lähdeniemi IAK, Heiniö C, Arias V, Havunen R, Cervera-Carrascon V, Santos JM, Sutinen E, Räsänen J, Borenius K, Mäyränpää MI, Aaltonen E, Sorsa S, Hemminki O, Kanerva A, Verschuren EW, Ilonen I, Hemminki A. Kudling TV, et al. Oncoimmunology. 2023 Aug 2;12(1):2241710. doi: 10.1080/2162402X.2023.2241710. eCollection 2023. Oncoimmunology. 2023. PMID: 37546696 Free PMC article. - Engineering Cancer Selective Virotherapies: Are the Pieces of the Puzzle Falling into Place?
Swift EA, Pollard SM, Parker AL. Swift EA, et al. Hum Gene Ther. 2022 Nov;33(21-22):1109-1120. doi: 10.1089/hum.2022.178. Epub 2022 Nov 4. Hum Gene Ther. 2022. PMID: 36178346 Free PMC article. Review. - Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.
Feola S, Russo S, Martins B, Lopes A, Vandermeulen G, Fluhler V, De Giorgi C, Fusciello M, Pesonen S, Ylösmäki E, Antignani G, Chiaro J, Hamdan F, Feodoroff M, Grönholm M, Cerullo V. Feola S, et al. Front Immunol. 2022 Apr 14;13:826164. doi: 10.3389/fimmu.2022.826164. eCollection 2022. Front Immunol. 2022. PMID: 35493448 Free PMC article. - Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector-Host Interactions.
Weklak D, Pembaur D, Koukou G, Jönsson F, Hagedorn C, Kreppel F. Weklak D, et al. Viruses. 2021 Jul 2;13(7):1300. doi: 10.3390/v13071300. Viruses. 2021. PMID: 34372506 Free PMC article. Review. - Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy.
Tessarollo NG, Domingues ACM, Antunes F, Luz JCDSD, Rodrigues OA, Cerqueira OLD, Strauss BE. Tessarollo NG, et al. Cancers (Basel). 2021 Apr 14;13(8):1863. doi: 10.3390/cancers13081863. Cancers (Basel). 2021. PMID: 33919679 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials